Home
Clinical Trials
TQB2930 Injection for the Tre...

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Last Updated: 2026-02-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

416 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-25

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

NCT07008976

Metastatic Breast Cancer

RECRUITING PHASE3

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

NCT06202261

Metastatic Breast Cancer Recurrent Breast Cancer Advanced Malignancies

RECRUITING PHASE1/PHASE2

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

NCT06115902

Breast Cancer

RECRUITING PHASE1

A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

NCT06798207

Gynecological Tumors

RECRUITING PHASE2

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

NCT07003074

Breast Cancer

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HER2-positive Advanced Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TQB2930+ chemotherapy

Subjects will receive TQB2930 injection in combination with chemotherapy agents on Day 1 (D1) of each cycle. TQB2930 will be administered at a dose of 30 mg/kg every 3 weeks (Q3W), Each treatment cycle lasts 21 days.

Group Type EXPERIMENTAL

TQB2930+ chemotherapy

Intervention Type DRUG

TQB2930 injection is a HER2 bispecific antibody drug； Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.

Trastuzumab+ chemotherapy

Subjects will receive trastuzumab in combination with chemotherapy agents on Day 1 (D1) of each cycle. The initial dose of trastuzumab is 8 mg/kg, followed by a maintenance dose of 6 mg/kg administered every 3 weeks (Q3W), Each treatment cycle lasts 21 days.

Group Type ACTIVE_COMPARATOR

Trastuzumab+ chemotherapy

Intervention Type DRUG

Trastuzumab is a HER2-specific targeted drug； Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TQB2930+ chemotherapy

Intervention Type DRUG

Trastuzumab+ chemotherapy

Trastuzumab is a HER2-specific targeted drug； Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects voluntarily participate in this study and sign the informed consent form;
* Age: 18-75 years (at time of signing Informed Consent Form (ICF); Eastern Cooperative Oncology Group (ECOG) performance status ≤1; estimated life expectancy \>3 months;
* Cytologically or histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive recurrent or metastatic breast cancer;
* Received ≥2 prior lines of anti-HER2 targeted therapy in the advanced setting;
* At least one measurable lesion meeting Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) criteria (excluding brain lesions);
* Willing to receive one of the investigator-selected chemotherapy regimens;
* Adequate organ function;
* Female subjects of childbearing potential must agree to use effective contraception (e.g., Intrauterine Device (IUD), oral contraceptives, or condoms) during the study and for 6 months after study completion.

Exclusion Criteria

* Concurrent Diseases and Medical History:

* Other malignancies within 5 years before randomization or concurrent malignancies (except adequately treated non-melanoma skin cancer, in situ cervical cancer, or other cancers with curative treatment and no recurrence for ≥3 years);
* Uncontrolled toxicities (\>CTCAE Grade 1) from prior therapies (excluding alopecia);
* Major surgery, open biopsy, or significant traumatic injury within 28 days before randomization;
* Non-healing wounds or fractures;
* Arterial/venous thromboembolic events within 6 months before randomization;
* History of drug abuse or psychiatric disorders that may affect compliance;
* Poorly controlled hypertension (e.g., Systolic Blood Pressure (SBP) \>160 mmHg despite treatment);
* ≥Grade 2 myocardial ischemia/infarction, arrhythmias, or congestive heart failure (New York Heart Association （NYHA）Class ≥II);
* Active or uncontrolled severe infections (≥CTCAE Grade 2);
* Known chronic hepatitis B;
* Active syphilis infection;
* Renal failure requiring hemodialysis/peritoneal dialysis;
* Immunodeficiency disorders (e.g., Human Immunodeficiency Virus (HIV) ;
* Poorly controlled diabetes;
* Urine protein ≥++ on dipstick with 24-hour urine protein \>1.0 g;
* Epilepsy requiring medication.
* Tumor-Related Conditions and Treatments:

* Chemotherapy, radiotherapy, or immunotherapy within 4 weeks before randomization (or within 5 half-lives of prior drugs, whichever is shorter);
* Chinese herbal medicines with approved antitumor indications (per National Medical Products Administration (NMPA) labeling) within 2 weeks;
* Severe Bone Lesions from bone metastases;
* Untreated brain metastases, Leptomeningeal metastases, or carcinomatous meningitis;
* Prior HER2-targeted therapy-induced Left Ventricular Ejection Fraction (LVEF) decline to \<50% or absolute reduction \>15%;
* Uncontrolled or symptomatic Hypertension requiring ongoing bisphosphonates;
* Uncontrolled cancer-related pain;
* Existed Lymphangitis Carcinomatosa or uncontrolled effusions;
* Use of Immunosuppressant or systemic corticosteroids (≥10 mg/day prednisone equivalent) within 2 weeks.
* Severe hypersensitivity to monoclonal antibodies;
* Participation in other antitumor clinical trials with investigational drugs within 4 weeks before randomization;
* Any condition deemed by the investigator to jeopardize subject safety or study completion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.